Brief: Akari Therapeutics Cash On Hand Expected To Be Sufficient To Fund Planned Operations Into September 2025
16/04/2025 13:26
April 16 (Reuters) - Akari Therapeutics PLC AKTX.O: AKARI THERAPEUTICS: CASH ON HAND EXPECTED TO BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO SEPTEMBER 2025 Source text: ID:nGNXbznLLZ Further company coverage: AKTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics